Her Natural Edge and In Her Corner Launch Conversational AI Companions to Support Menopause Awareness




Her Natural Edge and In Her Corner Launch Conversational AI Companions to Support Menopause Awareness

Alexandria, VA, Oct. 01, 2025 (GLOBE NEWSWIRE) — Her Natural Edge and In Her Corner announced the launch of Valerie and Jordan, two conversational voice companions developed to provide information and support around the topic of menopause. Valerie is designed for women experiencing menopause, while Jordan is intended for the men in their lives, including partners, family members, and friends.

In Her Corner

In Her Corner

The introduction of these tools coincides with Menopause Awareness Month in October, a period dedicated to increasing public understanding of a life stage that affects millions worldwide. By creating separate companions for women and men, Her Natural Edge and In Her Corner aim to encourage open dialogue and shared learning about menopause, a subject that is often overlooked in family and community conversations.

Valerie and Jordan are structured to function as conversational companions that communicate in a relatable, human-like manner. Users can engage with the AI as they would with a trusted peer, receiving guidance drawn from publicly available health information sources, including the World Health Organization (WHO) and the National Institutes of Health (NIH). The tools are not substitutes for medical advice or treatment but are intended to promote awareness and understanding of menopause and its related challenges.

Focus on Shared Experience

While menopause is primarily a biological transition for women, its impact extends beyond the individual. Families, particularly partners and close relatives, are often directly affected by the physical and emotional changes associated with this stage of life. Jordan was created to provide men with context and perspective, enabling them to better understand and support women during this time.

Valerie, meanwhile, was designed to address the needs of women navigating menopause firsthand. By offering conversational guidance, the companion serves as an accessible entry point into information and resources that can help women prepare for discussions with healthcare professionals, family members, or support groups.

“The goal was to create tools that make it easier for both women and men to engage in conversations about menopause,” said Don Wallace, spokesperson for Her Natural Edge and In Her Corner. “These companions are designed to encourage openness and provide a safe space to ask questions and seek information.”

Privacy and Confidentiality

In designing the AI companions, the teams at Her Natural Edge and In Her Corner emphasized privacy as a core principle. Conversations with Valerie and Jordan are not stored, recorded, or shared, ensuring that users can speak freely.

By eliminating data storage, the companions distinguish themselves from many other AI-based tools, focusing on confidentiality as an essential part of their design. This decision was made to reduce barriers for individuals who may feel hesitant to discuss sensitive health topics openly.

Availability and Access

Valerie is available for women through www.hernaturaledge.com, while Jordan can be accessed by men at www.inhercorner.net. Both resources are publicly accessible online and require no data collection to engage in conversation.

The separation of platforms reflects a recognition that women and men may approach menopause-related information differently. By tailoring the companions to these perspectives, the two organizations seek to provide clear, accessible entry points for each group.

Addressing a Wider Gap in Health Communication

Health experts and organizations have long identified menopause as an area where public awareness and education remain limited. Many women report gaps in information and support, while men frequently lack resources to help them understand what their partners, relatives, or colleagues may be experiencing.

The release of Valerie and Jordan by Her Natural Edge and In Her Corner is part of a growing effort within the health sector to address these communication challenges. While not offering medical guidance, the companions can serve as supplemental tools to help individuals and families prepare for more informed conversations with qualified professionals.

Commitment to Responsible Use of AI

The development of Valerie and Jordan follows a broader trend of applying artificial intelligence to health communication. Her Natural Edge and In Her Corner emphasized that both companions have been built in alignment with responsible AI principles. This includes ensuring transparency about their purpose, avoiding the storage of user conversations, and grounding information in reputable health sources.

The companions are not intended to provide medical advice, diagnose conditions, or replace healthcare consultations. Instead, they function as informational guides designed to make discussions about menopause more approachable and less stigmatized.

About Her Natural Edge and In Her Corner

Her Natural Edge and In Her Corner are dedicated platforms designed to provide accessible resources, information, and support for women navigating menopause and for the men who support them. Their initiatives focus on bridging communication gaps, encouraging dialogue within families and communities, and reducing stigma through open, informed conversations.

Her Natural Edge

Media Contact

Her Natural Edge / In Her Corner
Contact Person: Don Wallace
Email: support@hernaturaledge.com
Phone: +1 (703) 495-3277
Country: United States
Website: www.hernaturaledge.com | www.inhercorner.net

CONTACT: Media Contact
Her Natural Edge / In Her Corner
Contact Person: Don Wallace
Email: support@hernaturaledge.com
Phone: +1 (703) 495-3277
Country: United States
Website: www.hernaturaledge.com | www.inhercorner.net

OPA: Compromising Safety in the Name of Access




OPA: Compromising Safety in the Name of Access

TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) — Ontario’s mental health system is already under immense pressure, and the Ontario Psychological Association (OPA) warns that lowering professional standards will only make things worse. Recent CPBAO proposals threaten to strip away educational standards and safeguards, flooding the system with undertrained clinicians and putting the public at risk. Studies show that poorly trained providers are more likely to use unproven treatments and practice outside of their scopes, a dangerous gamble when dealing with complex conditions like depression, PTSD, autism, or ADHD. Psychologists and Psychological Associates have the advanced training needed in diagnosis, evidence-based care, ethics, and supervision to protect Ontarians and deliver effective outcomes.

With youth mental health needs increasing and diagnostic presentations becoming more complex, now is the time to strengthen quality, not dilute it. Lowering standards is not just bad policy, it’s a direct threat to public safety. The OPA appreciates all efforts to advance an innovative strategy that strengthens both the quality and accessibility of mental health services in Ontario. However, the changes proposed by the CPBAO veer drastically from nationally recognized and well-respected high standards in Ontario and some other provincial jurisdictions. They significantly reduce the number of training hours for Master’s level clinicians, while simultaneously reducing the safeguards, such as the comprehensive ethics exam and eliminating entirely the oral licensing exam, arguably the most important gatepost before all registrants become fully licensed.

Why should Ontarians be concerned about the government and CPBAO accepting one of the lowest standards of training and weakening or eliminating licensing exams in Ontario? For complex mental health issues, Ontarians need access to highly trained psychologists and psychological associates who can accurately evaluate presenting symptoms, rule out other possible diagnoses, and provide evidence-based care. This expertise and advanced knowledge are what maximize the chances of effective treatment outcomes and protect the quality of mental health services people rely on.

Psychologists play a critical role in Ontario’s mental health system by offering evidence-based treatment and the diagnostic clarity that physicians, psychiatrists, and even the courts rely on in complex cases, such as in neuropsychological, custody, and forensic evaluations. Accurate diagnosis is essential, and the cost of misdiagnosis is high, both for individuals and the system. While increasing access to psychological services must remain a priority, simply expanding the number of practitioners without ensuring sufficient training risks more misdiagnoses, greater public confusion about provider qualifications, rising costs through title upgrades without substance, and increased disability claims from a flood of novice diagnosticians. The proper path forward is to expand access while maintaining the standards of care Ontarians deserve.

Any proposed regulatory reform to the profession must safeguard quality and prioritize public protection, especially given Ontario’s growing youth mental health needs. We need to balance this with enhanced access. Ontario deserves the best of both when it comes to its mental health.

Any calls to lower the standards in this province in the name of access do not make sense.

“The OPA welcomes open dialogue on improving access to mental health care, but lowering professional standards is not the answer. Psychology has long been one of Ontario’s most trusted professions in healthcare. The best way forward is to work together on solutions that expand services while safeguarding the safety, quality, and trust that Ontarians expect and deserve.”

Dr. Laura Nichols, OPA President

In spite of the College Council’s recent vote for changes designed to lower the standards, the OPA will continue to advocate for retaining training and accreditation standards that ensure psychologists will remain the trusted professionals the public has known. We welcome constructive dialogue with the College and Ministry.

ABOUT THE ONTARIO PSYCHOLOGICAL ASSOCIATION
The Ontario Psychological Association (OPA) is a not-for-profit organization and the voluntary professional association representing psychology in Ontario. Its diverse membership, comprising clinicians, academics, researchers, and students, is dedicated to improving the mental health and well-being of Ontarians. The OPA provides leadership to promote mental health and well-being, inspiring excellence in the profession of psychology through research, education, clinical excellence, and advocacy.

Contact:
Mr. Richard Morrison
CEO
opa@psych.on.ca
416-961-5552

CJ Biomaterials launches new PHA platform for extrusion coatings in repulpable and home compostable food serviceware and food packaging applications




CJ Biomaterials launches new PHA platform for extrusion coatings in repulpable and home compostable food serviceware and food packaging applications

PHACT™ PHA semi-crystalline and amorphous grades combine to create PHA extrusion coatings that deliver excellent paper adhesion, sealing performance, and oil and grease resistance in a coating that sets the sustainability standard for end-of-life options

WOBURN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — CJ Biomaterials, Inc, a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, is introducing a new platform of PHA compounds for extrusion coating on paper and board used in food serviceware and food packaging applications designed for repulpability and home compostability certification. The new platform combines the properties of CJ’s unique amorphous (aPHA) and semi-crystalline PHAs (scPHA) to create fully biobased PHA compounds that produce a stable melt curtain during processing and serve as an excellent barrier against liquids, oils, grease, and fats. The new coatings also demonstrate outstanding adhesion to paper and board, passing seal testing and lip rolling trials for both hot and cold cups in addition to trays, bowls, and lids used for take-out foods.

After use, food serviceware items made with these PHACT™ PHA compounds can be composted in both home and commercial environments, facilitating the diversion of food scraps away from landfills and into compost. Additionally, the coatings have passed lab-scale trials in repulpability, creating flexibility to further accommodate variations in local composting and recycling infrastructure.

“Food service companies and brands are increasingly turning to biobased materials like paper and PHA biopolymers to create packaging that aligns with their sustainability commitments and fast-evolving extended producer responsibility legislation in the US,” said Max Senechal, Chief Commercial Officer. “This new platform demonstrates how we are accelerating the performance capabilities of new PHA compounds to meet the demand for products that won’t negatively impact human health or persist in our environment.”

PHACT™ PHA is food contact approved by the US FDA and certified as OK biodegradable MARINE, OK biodegradable SOIL, OK compost HOME, and OK compost INDUSTRIAL by TÜV Austria; commercially compostable by the Biodegradable Products Institute; and 100% biobased by the USDA BioPreferred program. Additionally, its inherent and certified biodegradability ensures that it will not contribute to the growing presence of persistent microplastics in the environment.

To learn more about PHACT™ PHA and its use in straws, cutlery, and flexible films, follow CJ Biomaterials on Linkedin or visit cjbiomaterials.com.

About CJ BIOMATERIALS
CJ Biomaterials, a business unit of global lifestyle company CJ CheilJedang, is a leading manufacturer of polyhydroxyalkanoate (PHA) biopolymers. The company’s proprietary PHACT™ PHA technology transforms carbon dioxide sequestered in plant sugars into innovative biopolymers through a unique, highly efficient fermentation process that produces both amorphous and semi-crystalline PHAs. These PHAs are certified biobased, compostable in home and commercial composting conditions, and biodegradable in marine and soil environments, and do not create persistent microplastics. CJ Biomaterials partners with brands across packaging, consumer goods, food service, nonwovens, and other industries to develop new materials and applications that reduce environmental impact while meeting rigorous performance standards. With headquarters in Seoul, Korea; offices in Woburn, MA, USA, and Frankfurt, Germany; and manufacturing facilities strategically positioned to serve global markets; CJ Biomaterials is committed to scaling sustainable material solutions that accelerate the transition to a circular bioeconomy. To learn more about CJ Biomaterials visit cjbiomaterials.com.

Photos accompanying this announcement are available at: 
https://www.globenewswire.com/NewsRoom/AttachmentNg/216c5a4f-3b36-4919-95de-f29f2e394801
https://www.globenewswire.com/NewsRoom/AttachmentNg/3bace72c-2fef-47e5-96dc-c1e0862053df

CONTACT: Media Contact
Resource Advantage
Dan Green
dgreen@resourceadvantage.com

CJ Biomaterials
Leah Ford
CJ.Biomaterials@cj.net

CJ Biomaterials launches new PHA platform for extrusion coatings in repulpable and home compostable food serviceware and food packaging applications




CJ Biomaterials launches new PHA platform for extrusion coatings in repulpable and home compostable food serviceware and food packaging applications

PHACT™ PHA semi-crystalline and amorphous grades combine to create PHA extrusion coatings that deliver excellent paper adhesion, sealing performance, and oil and grease resistance in a coating that sets the sustainability standard for end-of-life options

WOBURN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) — CJ Biomaterials, Inc, a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, is introducing a new platform of PHA compounds for extrusion coating on paper and board used in food serviceware and food packaging applications designed for repulpability and home compostability certification. The new platform combines the properties of CJ’s unique amorphous (aPHA) and semi-crystalline PHAs (scPHA) to create fully biobased PHA compounds that produce a stable melt curtain during processing and serve as an excellent barrier against liquids, oils, grease, and fats. The new coatings also demonstrate outstanding adhesion to paper and board, passing seal testing and lip rolling trials for both hot and cold cups in addition to trays, bowls, and lids used for take-out foods.

After use, food serviceware items made with these PHACT™ PHA compounds can be composted in both home and commercial environments, facilitating the diversion of food scraps away from landfills and into compost. Additionally, the coatings have passed lab-scale trials in repulpability, creating flexibility to further accommodate variations in local composting and recycling infrastructure.

“Food service companies and brands are increasingly turning to biobased materials like paper and PHA biopolymers to create packaging that aligns with their sustainability commitments and fast-evolving extended producer responsibility legislation in the US,” said Max Senechal, Chief Commercial Officer. “This new platform demonstrates how we are accelerating the performance capabilities of new PHA compounds to meet the demand for products that won’t negatively impact human health or persist in our environment.”

PHACT™ PHA is food contact approved by the US FDA and certified as OK biodegradable MARINE, OK biodegradable SOIL, OK compost HOME, and OK compost INDUSTRIAL by TÜV Austria; commercially compostable by the Biodegradable Products Institute; and 100% biobased by the USDA BioPreferred program. Additionally, its inherent and certified biodegradability ensures that it will not contribute to the growing presence of persistent microplastics in the environment.

To learn more about PHACT™ PHA and its use in straws, cutlery, and flexible films, follow CJ Biomaterials on Linkedin or visit cjbiomaterials.com.

About CJ BIOMATERIALS
CJ Biomaterials, a business unit of global lifestyle company CJ CheilJedang, is a leading manufacturer of polyhydroxyalkanoate (PHA) biopolymers. The company’s proprietary PHACT™ PHA technology transforms carbon dioxide sequestered in plant sugars into innovative biopolymers through a unique, highly efficient fermentation process that produces both amorphous and semi-crystalline PHAs. These PHAs are certified biobased, compostable in home and commercial composting conditions, and biodegradable in marine and soil environments, and do not create persistent microplastics. CJ Biomaterials partners with brands across packaging, consumer goods, food service, nonwovens, and other industries to develop new materials and applications that reduce environmental impact while meeting rigorous performance standards. With headquarters in Seoul, Korea; offices in Woburn, MA, USA, and Frankfurt, Germany; and manufacturing facilities strategically positioned to serve global markets; CJ Biomaterials is committed to scaling sustainable material solutions that accelerate the transition to a circular bioeconomy. To learn more about CJ Biomaterials visit cjbiomaterials.com.

Photos accompanying this announcement are available at: 
https://www.globenewswire.com/NewsRoom/AttachmentNg/216c5a4f-3b36-4919-95de-f29f2e394801
https://www.globenewswire.com/NewsRoom/AttachmentNg/3bace72c-2fef-47e5-96dc-c1e0862053df

CONTACT: Media Contact
Resource Advantage
Dan Green
dgreen@resourceadvantage.com

CJ Biomaterials
Leah Ford
CJ.Biomaterials@cj.net

Omada Health Launches “Meal Map,” an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting




Omada Health Launches “Meal Map,” an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting

The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement¹ with new real-time, personalized nutrition guidance

SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) — Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada’s Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence and long-term healthy habits.

In an era of increased GLP-1 use² and rising popularity of fad diets,³ people are confused about nutrition and are seeking sustainable approaches to health beyond restrictive dieting.⁴ Meal Map is designed to meet this need by helping members improve their relationship with food, moving away from categorizing foods as “good” or “bad” to an evidence-based,⁵ nutrient-dense approach. Focusing on nutrient-density has been proven to promote broad health benefits, including supporting a robust immune system,⁶ boosting energy levels,⁷ improving digestive health,⁸ and reducing the risk of cardiovascular diseases such as stroke and diabetes,⁹ as well as certain cancers.¹⁰

In a pilot program with over 1,000 members, Meal Map demonstrated promising early results, as members showed an increase in meal engagement compared to traditional approaches.¹ The tool provides instant feedback on nutrient composition of meals and delivers weekly progress reports on nutritional quality and water intake. Utilizing insights from tracked meals, members also receive recommendations for dietitian-vetted recipes through OmadaSpark, Omada’s AI-powered nutrition education tool that launched earlier this year.

“This evidence-based approach fills a critical gap in the market for a tool that moves beyond simple calorie counting and food restrictions, which isn’t always necessary to lose weight;⁵ instead, it focuses on nutritional value and food freedom,” said Justin Wu, MD, VP of Clinical Innovation and Quality at Omada Health. “By analyzing member behavior, gathering insights from our care teams, and listening to member feedback, we’ve developed a solution that provides actionable guidance for building lasting health habits – whether members are managing cardiometabolic conditions, using GLP-1 medications, or working towards broader health goals.”

Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work^®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Great Place to Work^® is the registered trademark of the Great Place to Work Institute and is used under license.

Contacts
Rose Ramseth
press@omadahealth.com

1. Omada Health. Meal Map Member Pilot. Unpublished. 2025
2. Evernorth. 2025 pharmacy in focus report [PDF]. Published March 2025. Accessed Sept 5, 2025. https://www.evernorth.com/sites/default/files/2025-03/2025-pharmacy-in-focus-report.pdf.
3. Tahreem A, Rakha A, Rabail R, et al. Fad Diets: Facts and Fiction. Front Nutr. 2022;9:960922. Published 2022 Jul 5. doi:10.3389/fnut.2022.960922
4. International Food Information Council. 2024 Food & Health Survey. Published June 20, 2024. Accessed Sept. 24, 2025. https://ific.org/research/2024-food-health-survey/
5. Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial. JAMA. 2018;319(7):667–679. doi:10.1001/jama.2018.0245
6. Munteanu C, Schwartz B. The relationship between nutrition and the immune system. Front Nutr. 2022;9:1082500. Published 2022 Dec 8. doi:10.3389/fnut.2022.1082500
7. Deligiannidou GE, Philippou E, Vasiari E, et al. Exploring the Relationship between Mediterranean Diet Adherence and Subjective Well-Being among Greek and Cypriot Adults. Nutrients. 2024;16(8):1238. Published 2024 Apr 21. doi:10.3390/nu16081238
8. Sasson AN, Ingram RJM, Raman M, Ananthakrishnan AN. Nutrition in the Management of Inflammatory Bowel Diseases. Gastroenterol Clin North Am. 2021;50(1):151-167. doi:10.1016/j.gtc.2020.10.001
9. Micha R, Peñalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA. 2017;317(9):912–924. doi:10.1001/jama.2017.0947
10. Nobs SP, Zmora N, Elinav E. Nutrition Regulates Innate Immunity in Health and Disease. Annu Rev Nutr. 2020;40:189-219. doi:10.1146/annurev-nutr-120919-094440

Omada Health Launches “Meal Map,” an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting




Omada Health Launches “Meal Map,” an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting

The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement¹ with new real-time, personalized nutrition guidance

SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) — Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada’s Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence and long-term healthy habits.

In an era of increased GLP-1 use² and rising popularity of fad diets,³ people are confused about nutrition and are seeking sustainable approaches to health beyond restrictive dieting.⁴ Meal Map is designed to meet this need by helping members improve their relationship with food, moving away from categorizing foods as “good” or “bad” to an evidence-based,⁵ nutrient-dense approach. Focusing on nutrient-density has been proven to promote broad health benefits, including supporting a robust immune system,⁶ boosting energy levels,⁷ improving digestive health,⁸ and reducing the risk of cardiovascular diseases such as stroke and diabetes,⁹ as well as certain cancers.¹⁰

In a pilot program with over 1,000 members, Meal Map demonstrated promising early results, as members showed an increase in meal engagement compared to traditional approaches.¹ The tool provides instant feedback on nutrient composition of meals and delivers weekly progress reports on nutritional quality and water intake. Utilizing insights from tracked meals, members also receive recommendations for dietitian-vetted recipes through OmadaSpark, Omada’s AI-powered nutrition education tool that launched earlier this year.

“This evidence-based approach fills a critical gap in the market for a tool that moves beyond simple calorie counting and food restrictions, which isn’t always necessary to lose weight;⁵ instead, it focuses on nutritional value and food freedom,” said Justin Wu, MD, VP of Clinical Innovation and Quality at Omada Health. “By analyzing member behavior, gathering insights from our care teams, and listening to member feedback, we’ve developed a solution that provides actionable guidance for building lasting health habits – whether members are managing cardiometabolic conditions, using GLP-1 medications, or working towards broader health goals.”

Omada Health
Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 30 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work^®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Great Place to Work^® is the registered trademark of the Great Place to Work Institute and is used under license.

Contacts
Rose Ramseth
press@omadahealth.com

1. Omada Health. Meal Map Member Pilot. Unpublished. 2025
2. Evernorth. 2025 pharmacy in focus report [PDF]. Published March 2025. Accessed Sept 5, 2025. https://www.evernorth.com/sites/default/files/2025-03/2025-pharmacy-in-focus-report.pdf.
3. Tahreem A, Rakha A, Rabail R, et al. Fad Diets: Facts and Fiction. Front Nutr. 2022;9:960922. Published 2022 Jul 5. doi:10.3389/fnut.2022.960922
4. International Food Information Council. 2024 Food & Health Survey. Published June 20, 2024. Accessed Sept. 24, 2025. https://ific.org/research/2024-food-health-survey/
5. Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial. JAMA. 2018;319(7):667–679. doi:10.1001/jama.2018.0245
6. Munteanu C, Schwartz B. The relationship between nutrition and the immune system. Front Nutr. 2022;9:1082500. Published 2022 Dec 8. doi:10.3389/fnut.2022.1082500
7. Deligiannidou GE, Philippou E, Vasiari E, et al. Exploring the Relationship between Mediterranean Diet Adherence and Subjective Well-Being among Greek and Cypriot Adults. Nutrients. 2024;16(8):1238. Published 2024 Apr 21. doi:10.3390/nu16081238
8. Sasson AN, Ingram RJM, Raman M, Ananthakrishnan AN. Nutrition in the Management of Inflammatory Bowel Diseases. Gastroenterol Clin North Am. 2021;50(1):151-167. doi:10.1016/j.gtc.2020.10.001
9. Micha R, Peñalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States. JAMA. 2017;317(9):912–924. doi:10.1001/jama.2017.0947
10. Nobs SP, Zmora N, Elinav E. Nutrition Regulates Innate Immunity in Health and Disease. Annu Rev Nutr. 2020;40:189-219. doi:10.1146/annurev-nutr-120919-094440

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase




Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share (“Warrants”) from Oramed Pharmaceuticals Inc. (“Oramed”) for $13,000,000. As previously disclosed, Scilex entered into an option agreement with Oramed for the repurchase of Warrants, pursuant to which, among other things, Oramed granted an option to Scilex to repurchase 6,500,000 warrants in two tranches for an aggregate purchase price of $27,000,000. Scilex continues to have the option to repurchase the remaining 3,370,000 warrants from Oramed for $14,000,000 on or before December 31, 2025.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, repurchase of warrants, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the previously announced transactions with Datavault AI Inc., and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase




Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase

PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share (“Warrants”) from Oramed Pharmaceuticals Inc. (“Oramed”) for $13,000,000. As previously disclosed, Scilex entered into an option agreement with Oramed for the repurchase of Warrants, pursuant to which, among other things, Oramed granted an option to Scilex to repurchase 6,500,000 warrants in two tranches for an aggregate purchase price of $27,000,000. Scilex continues to have the option to repurchase the remaining 3,370,000 warrants from Oramed for $14,000,000 on or before December 31, 2025.

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, repurchase of warrants, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the previously announced transactions with Datavault AI Inc., and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions




SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli^™ as the first FDA-approved ready-to-use oral suspension

COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized multiple commercial group purchasing organization (GPO) agreements for Arbli^TM (losartan potassium) Oral Suspension, 10 mg/mL, providing access to more than 2500 healthcare institutions, including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, representing potential penetration into an estimated 20% of the U.S. institutional market while also establishing a broad footprint across long-term care and outpatient facilities.

“Securing these GPO agreements is a pivotal milestone for Scienture and for Arbli^™,” commented Narasimhan Mani, President and co-CEO of Scienture. “By gaining access to more than 2500 healthcare institutions, we are positioning Arbli™ to reach the patients and providers who need it most. Looking ahead, we plan to further expand our GPO partnerships and direct contracts to deepen institutional market penetration nationwide. This strategy underscores our commitment to creating meaningful growth opportunities and long-term value for shareholders.”

Arbli^TM is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli^TM is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli^TM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

According to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately $256 million in annual sales and a prescription volume of 71 million (TRx), with all currently marketed products available only in oral solid form.

“GPO agreements often serve as a strategic gateway,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “Once a product is listed on a contract, it becomes accessible to all member institutions, enabling adoption to scale rapidly without renegotiating individual agreements. These agreements highlight a significant opportunity for Arbli™ as the first FDA-approved, ready-to-use oral suspension.”

About Arbli^TM

Arbli^TM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli^TM is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take Arbli^TM when pregnant. When pregnancy is detected, discontinue Arbli^TM as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli^TM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer Arbli^TM with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli^TM in patients with renal impairment (GFR <60 mL/min).
• Do not administer Arbli^TM in patients with severe hepatic impairment. Arbli^TM has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions




SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli^™ as the first FDA-approved ready-to-use oral suspension

COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized multiple commercial group purchasing organization (GPO) agreements for Arbli^TM (losartan potassium) Oral Suspension, 10 mg/mL, providing access to more than 2500 healthcare institutions, including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, representing potential penetration into an estimated 20% of the U.S. institutional market while also establishing a broad footprint across long-term care and outpatient facilities.

“Securing these GPO agreements is a pivotal milestone for Scienture and for Arbli^™,” commented Narasimhan Mani, President and co-CEO of Scienture. “By gaining access to more than 2500 healthcare institutions, we are positioning Arbli™ to reach the patients and providers who need it most. Looking ahead, we plan to further expand our GPO partnerships and direct contracts to deepen institutional market penetration nationwide. This strategy underscores our commitment to creating meaningful growth opportunities and long-term value for shareholders.”

Arbli^TM is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli^TM is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli^TM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

According to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately $256 million in annual sales and a prescription volume of 71 million (TRx), with all currently marketed products available only in oral solid form.

“GPO agreements often serve as a strategic gateway,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “Once a product is listed on a contract, it becomes accessible to all member institutions, enabling adoption to scale rapidly without renegotiating individual agreements. These agreements highlight a significant opportunity for Arbli™ as the first FDA-approved, ready-to-use oral suspension.”

About Arbli^TM

Arbli^TM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli^TM is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take Arbli^TM when pregnant. When pregnancy is detected, discontinue Arbli^TM as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli^TM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer Arbli^TM with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli^TM in patients with renal impairment (GFR <60 mL/min).
• Do not administer Arbli^TM in patients with severe hepatic impairment. Arbli^TM has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com